Sponsored Talks
Valentina Millarte (Agilent Technologies)
Title: Real-Time Cellular Metabolism Analysis: Agilent Seahorse Analyzers and Integrated Microscopy for Comprehensive Mitochondrial and Glycolytic Function Profiling
Mitochondrial function and glycolysis play critical roles in a variety of vital cellular processes, including cellular activation, proliferation, differentiation, cell death, and disease progression. Agilent offers solutions that enable the measurement of metabolic parameters and functions using live cells, in real-time, in a microplate. The Agilent Seahorse Analyzers profile cellular metabolic functions, using label-free, solid-state disposable optical sensors. Seahorse simultaneously measure mitochondrial respiration via the oxygen consumption rate (OCR), and glycolysis via the extracellular acidification rate (ECAR). Seamless integration with the Agilent BioTek Cytation 5 allows easy and accurate normalization through imaging. Assay kits and reagents provide standard methods for quantifying mitochondrial respiration, glycolytic activity, endogenous and exogenous fatty acid oxidation, substrate oxidation, and metabolic phenotype. In addition, Agilent’s soluble sensors offer a simple kinetic measurement of aerobic metabolism that can be performed in microplate format using fluorescence plate readers such as the Agilent BioTek Synergy H1. These technologies have been applied to multiple research areas, including cancer, obesity, diabetes, metabolic disorders, immunology, cardiovascular function, neurodegeneration, virology, and aging.
Krista Rantanen (The Baker Company)
Title: Making small changes for big impact - paradigm shift from normoxia to physoxia
Dr. Rantanen is the Director of Scientific Applications at the Baker Company. In addition, she is a visiting scientist at the Francis Crick Institute in London, UK.
Dr. Rantanen is also the lead of HypoxEU and HypoxAmericas, a global network of scientists that share the interest in the effects of oxygen in biomedical research.
In the lecture presented by Dr. Rantanen will discuss the importance of oxygen in general and its impact on biomolecules in particular. She will give an overview of the effect varying oxygen levels have for example in stem cell research and drug development success of biopharma companies.
In addition she will discuss why paradigm shifts are so difficult in science and how to make the change possible.
Lisa Schweizer (OmicVision Biosciences ApS)
Online Talk - Title: AI-Powered Spatial Proteomics Unlocks Insights into Pancreatic Cancer
Deep Visual Proteomics (DVP) is a novel technology that captures the proteome of healthy and diseased cells while preserving their exact spatial localization. DVP integrates high-content imaging, AI-based image analysis, single-cell isolation via high-precision laser microdissection, and ultra-sensitive mass spectrometry-based proteomics. By combining DVP with state-of-the-art pathology foundation models, we have developed a platform to identify cell-type specific, druggable protein targets across diverse indications. Our method resolves cellular heterogeneity of diseases in synergy with clinical pathology and offers clinicians disease-relevant therapeutic options at the individual level. We demonstrate this approach in pancreatic ductal adenocarcinoma (PDAC) by systematically characterizing key regions of interest (ROIs) in its precursor lesion (PanIN) using organ donor samples. Achieving a proteomic depth of over 6,000 proteins from approximately 100 phenotype-matched cells per sample, we unveil stage-specific molecular signatures in PanIN lesions, including the progressive activation of KRAS signaling. This first-of-its-kind dataset enables the creation of detailed, phenotype-specific, and spatially resolved proteomic landscapes of PDAC carcinogenesis. The goal of precision medicine is to match the right drug to the right patient. Our spatial proteomic approach translates recent technological advances from discovery to the clinic, identifying novel and druggable protein targets.
Sara Milosevic (10x Genomics)
Title: Experience the power of the Xenium platform
Xenium is an end-to-end platform from 10x Genomics that enables high-throughput subcellular mapping of up to 5,000 genes alongside multiplexed protein in the same tissue section. Compatible with fresh frozen (FF) and formalin-fixed, paraffin-embedded (FFPE) tissues, the platform includes the Xenium Analyzer, a versatile and easy-to-use instrument; sensitive and specific chemistry; multimodal cell segmentation; a diverse menu of customizable panels; and software. Data can be visualized with the intuitive Xenium Explorer or communitydeveloped analysis tools. As with other 10x Genomics products, the Xenium platform has a robust roadmap to enhance the core platform with more capabilities and analytes.
Joins us to discover in 10 minutes how we change the game in onco, immuno and neurosciences researches.
